Abivax, founded by Truffle Capital in 2013, is a late clinical-stage BioTech company focused on developing therapies that leverage the body's natural regulatory mechanisms to stabilize immune responses. Their leading drug candidate, Obefazimod, is being explored as a potential treatment for patients with chronic inflammatory diseases such as Ulcerative Colitis (UC) and Crohn’s Disease (CD).